Compare Synchrony Financial (SYF) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synchrony Financial vs 10X Genomics Inc — how do they compare? Synchrony Financial trades at $77.5 (market cap $25.58B), while 10X Genomics Inc trades at $67.59 (market cap $8.55B). The key difference: Synchrony Financial is far larger — about 3× 10X Genomics Inc's market cap, and Synchrony Financial pays a 1.73% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| SYF | TXG | |
|---|---|---|
Market Cap | $25.58B | $8.55B |
Sector | Financials | Health |
52-Week High | $88.47 | $67.29 |
52-Week Low | $63.78 | $11.34 |
Dividend Yield | 1.73% | — |
Enterprise Value | — | $8.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synchrony Financial (SYF) trades at $78.62, down 1.63% on the day, with a neutral technical signal. The stock shows strong fundamentals with a low P/E of 8.06 and robust profitability, including a 23.4% net income margin and 22.23% ROE. Recent earnings beats and a strategic partnership with OpenAI for AI-driven commerce highlight growth initiatives. Analyst consensus is bullish with a $87.33 price target and no sell ratings.
The outlook remains positive given valuation appeal, consistent earnings performance, and AI partnership potential. Key risks include consumer credit deterioration amid economic uncertainty and increased investing cash outflows. Institutional ownership trends and strong buyback activity support the bullish case, but credit quality monitoring is essential.
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
